Literature DB >> 18376307

Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.

Aiqun Xue1, Christopher J Scarlett, Christopher J Jackson, Barry J Allen, Ross C Smith.   

Abstract

OBJECTIVES: To determine the diagnostic and prognostic significance of growth factors and the urokinase-type plasminogen activator (uPA) system in pancreatic ductal adenocarcinoma (PDAC) using a multigene assay.
METHODS: Messenger RNA (mRNA) expression of 15 genes from epidermal growth factor receptor, insulin-like growth factor (IGF), and uPA families were measured in 46 PDAC tissue samples using quantitative real-time reverse transcription-polymerase chain reaction. These results were compared with those of the uninvolved adjacent (AP) tissue and benign mucinous cystadenomas (BMC). The mRNA expression was evaluated using logistic regression and receiver operating characteristic area under the curve (ROC AUC) analyses. Their relationship with prognosis was tested by Cox regression multivariate analysis.
RESULTS: All genes were overexpressed in most of the PDAC tissue. When compared with AP tissue, the median expression values for IGF-binding protein 3 (IGFBP-3) and uPA receptor (uPAR) was 9.8- and 9.6-fold, respectively. Expression levels of uPA, uPAR, IGF-I, and IGFBP-3 mRNA were significantly greater in PDAC than in BMC. The IGFBP-3 mRNA expression demonstrated greatest ROC AUC values for PDAC versus AP tissue (ROC AUC, 0.745; 95% confidence interval [CI], 0.65-0.86); whereas ROC AUC values were greatest for uPAR when PDAC was compared with BMC (ROC AUC, 0.846; 95% CI, 0.76-0.94). The combination of uPA, uPAR, and IGF-I significantly improved discriminatory power (ROC AUC, 0.965; 95% CI, 0.93-1.00). The IGFBP-3, uPA, plasminogen activator inhibitor-2, and International Union Against Cancer stage had a significant influence on survival, but the effect of IGFBP-3 was lost after multivariate stepwise analysis.
CONCLUSIONS: These results indicate that there is an influence of IGF system in tumor progression from BMC to PDAC, whereas the uPA/uPAR system has the greater influence on survival in PDAC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376307     DOI: 10.1097/MPA.0b013e31815750f0

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  28 in total

1.  Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.

Authors:  Helene Damhofer; Jan Paul Medema; Veronique L Veenstra; Liviu Badea; Irinel Popescu; Henk Roelink; Maarten F Bijlsma
Journal:  Mol Oncol       Date:  2013-08-16       Impact factor: 6.603

2.  Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure.

Authors:  Alireza Aslani; Anthony J Gill; Paul J Roach; Barry J Allen; Ross C Smith
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

3.  Clinicopathological significance and impact on outcomes of the gene expression levels of IGF-1, IGF-2 and IGF-1R, IGFBP-3 in patients with colorectal cancer: Overexpression of the IGFBP-3 gene is an effective predictor of outcomes in patients with colorectal cancer.

Authors:  Naoto Yamamoto; Takashi Oshima; Kazue Yoshihara; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Manabu Shiozawa; Takaki Yoshikawa; Soichiro Morinaga; Yasushi Rino; Chikara Kunisaki; Katsuaki Tanaka; Makoto Akaike; Toshio Imada; Munetaka Masuda
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

4.  Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage.

Authors:  Melissa W Y Chua; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

5.  Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Dijie Liu; Douglas Overbey; Lisa Watkinson; Michael F Giblin
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

6.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

Review 7.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

8.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

9.  Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.

Authors:  Calvin L Cole; John F Bachman; Jian Ye; Joseph Murphy; Scott A Gerber; Christopher A Beck; Brendan F Boyce; Gowrishankar Muthukrishnan; Joe V Chakkalakal; Edward M Schwarz; David Linehan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-05-07       Impact factor: 12.910

10.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.